BioLineRx Doses First Patient for BL-8040’s Second Indication as Novel Stem Cell Mobilization Treatment

JERUSALEM–(BUSINESS WIRE)–BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today dosing of the first patient in a Phase …

[Read the full article here]

Comments are closed.